Skip to Content

Thiotepa Pregnancy and Breastfeeding Warnings

Thiotepa is also known as: Tepadina, Thioplex

Medically reviewed on August 4, 2017.

Thiotepa Pregnancy Warnings

In one patient, thiotepa was used during the second and third trimesters without any apparent fetal harm.

Thiotepa has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of teratogenicity and lethality, as well as inhibiting implantation when instilled Into the uterine cavity and interfering with spermatogenesis. There are no controlled data in human pregnancy. Thiotepa should only be given during pregnancy when there are no alternatives and benefit outweighs risk. Patients of childbearing potential should be advised to avoid pregnancy. If thiotepa is used during pregnancy, or if pregnancy occurs during therapy, the patient and partner should be apprised of the potential hazard to the fetus.

See references

Thiotepa Breastfeeding Warnings

There are no data on the excretion of thiotepa into human milk. Because many drugs are excreted in human milk and because thiotepa has shown potential for tumorigenicity in animal studies, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 5th ed." Baltimore, MD: Williams & Wilkins (1998):
  2. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.

References for breastfeeding information

  1. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide